TITLE

Sentinel Case of *Candida auris* in the Western United States Following Prolonged Occult Colonization in a Returned Traveler from India

AUTHORS AND AFFILIATIONS

Michael H. Woodworth*[1], David Dynerman[2]*, Emily D. Crawford[2], Lucy M. Li[2], Sarah B. Doernberg[3], Lynn Ramirez-Avila[4], Paula Hayakawa Serpa[2,3], Amy Nichols[5], Amy Lyden[2], Cristina M. Tato[2], Steve Miller[6], Joseph L. Derisi[2,7], Charles Langelier[2,3].

*equal contributions

[1]Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

[2]Chan Zuckerberg Biohub, San Francisco CA

[3]Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, CA, USA

[4]Department of Pediatrics, Division of Pediatric Infectious Diseases and Global Health, University of California, San Francisco, CA, USA

[5]Hospital Epidemiology and Infection Control, University of California, San Francisco, CA, USA

[6]Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA

[7]Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA

24 **KEYWORDS**

25 *Candida auris*, emerging infection, antimicrobial resistance, echinocandin resistance,

26 metagenomic

27

28 **RUNNING TITLE**

29 Emergence of *Candida auris* in Western USA

FOOTNOTE PAGE

Conflict of interest statement: The authors do not have a commercial or other association that might pose a conflict of interest

FUNDING

NCATS TL1 TR002382, NIAID UM1AI104681(Woodworth M).

NHLBI K12HL119997, Nina Ireland Foundation, Marcus Foundation (Langelier C)

NIAID P01AI091575 and the Chan Zuckerberg Biohub (Crawford ED and DeRisi JL)

PRIOR PRESENTATION: This work has not been previously presented at any meetings.

CORRESPONDING AUTHOR CONTACT INFORMATION

Charles Langelier, MD, PhD

Division of Infectious Diseases, Department of Medicine

1700 4th St, Room 403 San Francisco CA, 94158

chaz.langelier@ucsf.edu

ABSTRACT

Candida auris is an emerging multidrug-resistant yeast with high mortality. We report the sentinel *C. auris* case on the United States West Coast in a patient who relocated from India. We identified close phylogenetic relatedness to the South Asia clade and *ERG11* Y132F and *FKS1* S639Y mutations potentially explaining antifungal resistance.

Introduction

Candida auris is an emerging fungal pathogen with high minimum inhibitory concentrations (MIC) for many antifungals. Since identification in 2009, it is increasingly recognized as an important cause of invasive disease and nosocomial outbreaks, with high associated in-hospital mortality of 40-72%(1). Genomic evaluation of strains from multiple geographic regions suggests simultaneous emergence of distinct geographic clades on three continents, as opposed to dissemination from a single source (1). This observation suggests environmental factors such as increased antifungal use may have contributed to *C. auris* emergence(1).

In addition to high fluconazole MICs, *C. auris* isolates also frequently have high MICs for other antifungals including amphotericin and less frequently echinocandins(1). Despite the alarming frequency of elevated antifungal MICs in *C. auris*, the underlying mechanisms and alleles associated with this resistance have not been fully characterized. In *C. auris* as well as in other *Candida* species, mutations in *ERG11* (ergosterol synthetase), *FKS1* (1,3 beta-D-glucan synthetase) and *FUR1* (uracil phosphoribosyltransferase) have been associated with resistance to fluconazole, echinocandins and flucytosine, respectively(1, 2). Previous studies suggest that mutations in these genes can arise in the setting of systemic antifungal therapy(3).

Despite first appearing in the eastern United States in 2013, *C. auris* had not been detected on the US West Coast(2). Here we report the identification of *C. auris* in this region, which was unusual in that it did not establish endemicity, and use whole genome sequencing (WGS) to identify strain origin and evaluate genetic mechanisms of antifungal resistance.

Methods

Case description

An elderly man with metastatic rectal cancer relocated from India to California. He had received chemotherapy and radiation while in India and had also undergone intraabdominal surgeries complicated by sepsis. In the year following his move, he required multiple admissions to the University of California, San Francisco Medical Center (UCSF) for management of his malignancy and for secondary infections with carbapenem-resistant *Enterobacteriaceae* (CRE), for which he was placed in contact isolation. During his initial multi-month admission, two cultures from his urostomy grew 10,000 colony forming units of a non-*Candida albicans* yeast that was not further speciated due to unclear clinical significance. In the course of his care, he was treated with echinocandins with prophylactic intent. Several months after initial admission, he was transitioned to palliative care. Three days prior to death, a nephrostomy culture returned positive for yeast, which was ultimately speciated as *Candida auris.*

Clinical microbiology and antifungal susceptibility testing

Urine collected from the patient's nephrostomy tube into a sterile container underwent quantitative culture for bacteria and yeast using standard culture methods. Species identification was made using MALDI-TOF mass spectrometry (Brucker Diagnostics), which returned a score value of 2.14, and was additionally confirmed by the California Department of Public Health. Antifungal susceptibility testing was performed using Sensititre YeastOne MIC plates (Trek Diagnostic Systems, Inc.), which

has >95% agreement with the Clinical Laboratory Standards Institute reference method.(4)

Whole genome sequencing

DNA was extracted from the cultured *C. auris* isolate using the Zymo ZR Bacterial/Fungal DNA kit. Library preparation was completed with the New England Biolabs NEBNext Ultra II DNA library prep kit and WGS was performed using an Illumina NextSeq. The same DNA also underwent library prep using the Oxford Nanopore Rapid Low Input by PCR Barcoding Kit and WGS on a MinION instrument.

Genome assembly, phylogenetic analyses and antifungal resistance gene analysis

Raw Illumina sequencing reads were quality filtered using PriceSeqFilter(5) and then parsed with Nanopore reads for hybrid *de novo* assembly using DBG2OLC (6). Reference-based whole genome phylogenetic analysis constructed from core genome single nucleotide polymorphisms (SNPs) was carried out with the NASP pipeline(7) using Pakistan strain B8441 as the reference genome and incorporating genomes from Lockhart et al.(1) as well as *C. auris* isolate 16B15b containing the *FKS1* S639P mutation identified by Rhodes et al (3). RAxML-ng (8) was used to build maximum likelihood phylogenetic trees as detailed in Supplemental Methods. To identify genetic mutations associated with fluconazole or echinocandin resistance, Illumina sequences were aligned against *ERG11* (Genbank KY410388.1) and *FKS1* (Genbank XM_018312471.1) using BowTie2(9). Mutations were confirmed by *ERG11* and *FKS1*

PCR followed by Sanger Sequencing (Table S1) following previously described methods.(10)

Results

Assembly and Phylogenetic Characteristics

De novo hybrid assembly of Illumina and Oxford Nanopore reads produced a total of 33 contigs spanning 12 Megabases (Mb), characterized by 44.9% GC content, consistent with prior estimates(1, 3). Whole genome phylogenetic analysis based on a core genome of 208,384 SNPs placed this isolate within the South Asia clade (Figure A). On average, 56 SNPs separated this isolate from others from the South Asia clade (Figure B).

Phenotypic and Genotypic Assessment of Antifungal Resistance

The California isolate demonstrated low MICs to amphotericin (1 µg/mL), flucytosine (0.5 µg/mL), and voriconazole (0.032 µg/mL). The isolate had an elevated fluconazole MIC of 32 µg/mL. Assessment of this isolate's *ERG11* (encoding ergosterol synthetase) allele revealed the well-characterized Y132F substitution in the azole resistance hotspot region (1, 3). Unlike most *C. auris* strains, this California isolate also exhibited a high caspofungin MIC of 8 µg/mL. Interrogation of *FKS1* (encoding (1,3)-β-D-glucan synthetase) revealed a S639Y mutation in the echinocandin resistance hotspot 1 region (Table S1) (3, 10).

Discussion

C. auris emerges on the West Coast of the United States

Here we report the first case of *C. auris* on the US West Coast, a region that had no previous reports of the pathogen despite emergence in New York in 2013. The patient's history of healthcare exposure in India combined with the clustering of his *C. auris* isolate with the South Asia clade by WGS phylogenetic analysis suggests that he acquired *C. auris* abroad prior to hospitalization in California. This finding supports current guidance from the US Centers for Disease Control and Prevention to speciate all *Candida* in high risk patients including those from regions of high *C. auris* prevalence, to allow for early implementation of infection control measures(1, 11). Following identification of *C. auris*, enhanced infection control measures were implemented at UCSF including surface disinfection, a unit-level point prevalence survey and prospective surveillance. No additional cases of *C. auris* at our medical center have been identified in over a year. This case represents an unusual interruption in spread and prolonged healthcare environmental contamination that has been characteristic of detection of healthcare-associated *C. auris.* Early implementation of contact precautions for CRE may have contributed to curbing transmission of *C. auris* in this case.

This isolate had a high fluconazole MIC with an observed *ERG11* Y132F mutation (1, 3). The California *C. auris* isolate also demonstrated a high echinocandin MIC, which is observed in less than 10% of *C. auris* strains (1). It is possible that this patient's prophylactic treatment with echinocandins could have selected for resistance as observed in this isolate. This *C. auris* isolate also had a *FKS1* hotspot-1 region mutation, which has been associated with echinocandin resistance in multiple other

168 *Candida* species (3, 10). The identified *FKS1* S639 substitutions of nonpolar residues
169 (Y,F,P) has also been identified in other *C. auris* strains with high echinocandin MIC
170 values, suggesting a key role for this amino acid in echinocandin resistance (3, 10).
171 Further study is needed to estimate the prevalence and duration of colonization
172 by this emerging pathogen. Future work using WGS is needed to clarify the origins of *C.*
173 *auris,* transmission patterns, and mechanisms of resistance to prevent and manage this
174 emerging fungal pathogen of global significance.
175

176 **FUNDING**
177 This work was supported by the National Center for Advancing Translational Sciences
178 [grant number TL1 TR002382 to MHW], the National Institute for Allergy and Infectious
179 Disease [UM1AI104681 to MHW, P01AI091575 to CL], the National Heart, Lung, and
180 Blood Institute [NHLBI K23HL138461-01A1 to CL], and the Chan Zuckerberg Biohub
181 [JLD]. The content is solely the responsibility of the authors and does not necessarily
182 represent the official views of the National Institutes of Health.
183

184 **DATA AVAILABILITY**
185 Raw sequences are available via Bioproject ID PRJNA480539.

REFERENCES

1. **Lockhart SR**, **Etienne KA**, **Vallabhaneni S**, **Farooqi J**, **Chowdhary A**, **Govender NP**, **Colombo AL**, **Calvo B**, **Cuomo CA**, **Desjardins CA**, **Berkow EL**, **Castanheira M**, **Magobo RE**, **Jabeen K**, **Asghar RJ**, **Meis JF**, **Jackson B**, **Chiller T**, **Litvintseva AP**. 2017. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses **64**.
2. **Vallabhaneni S**, **Kallen A**, **Tsay S**, **Chow N**, **Welsh R**, **Kerins J**, **Kemble SK**, **Pacilli M**, **Black SR**, **Landon E**, **Ridgway J**, **Palmore TN**, **Zelzany A**, **Adams EH**, **Quinn M**, **Chaturvedi S**, **Greenko J**, **Fernandez R**, **Southwick K**, **Furuya EY**, **Calfee DP**, **Hamula C**, **Patel G**, **Barrett P**, **Lafaro P**, **Berkow EL**, **Moulton-Meissner H**, **Noble-Wang J**, **Fagan RP**, **Jackson BR**, **Lockhart SR**, **Litvintseva AP**, **Chiller TM**. 2016. Investigation of the First Seven Reported Cases of *Candida auris,* a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep **65**:1234–1237.
3. **Rhodes J**, **Abdolrasouli A**, **Farrer RA**, **Cuomo CA**, **Aanensen DM**, **Armstrong-James D**, **Fisher MC**, **Schelenz S**. 2018. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect **7**.
4. **Cuenca-Estrella M**, **Gomez-Lopez A**, **Alastruey-Izquierdo A**, **Bernal-Martinez L**, **Cuesta I**, **Buitrago MJ**, **Rodriguez-Tudela JL**. 2010. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre Ye. J Clin Microbiol **48**:1782–1786.
5. **Ruby JG**, **Bellare P**, **Derisi JL**. 2013. PRICE: software for the targeted assembly of components of (Meta) genomic sequence data. G3 (Bethesda) **3**:865–880.
6. **Ye C**, **Hill CM**, **Wu S**, **Ruan J**, **Ma ZS**. 2016. DBG2OLC: Efficient Assembly of Large Genomes Using Long Erroneous Reads of the Third Generation Sequencing Technologies. Sci Rep **6**:31900.
7. **Roe C**, **Smith DE**, **Williamson CHD**, **Aziz M**, **Keim P**, **Hepp CM**, **Driebe EM**, **Lemmer D**, **Travis J**, **Hicks ND**, **Schupp JM**, **Wagner DM**, **Engelthaler DM**, **Gillece JD**, **Sahl JW**, **Drees KP**. 2016. NASP: an accurate, rapid method for the identification of SNPs in WGS datasets that supports flexible input and output formats. Microb Genomics **2**.
8. **Alexey Kozlov**. 2018. amkozlov/raxml-ng: RAxML-NG v0.6.0 BETA. Zenodo.
9. **Langmead B**, **Salzberg SL**. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods **9**:357–359.
10. **Chowdhary A**, **Prakash A**, **Sharma C**, **Kordalewska M**, **Kumar A**, **Sarma S**, **Tarai B**, **Singh A**, **Upadhyaya G**, **Upadhyay S**, **Yadav P**, **Singh PK**, **Khillan V**, **Sachdeva N**, **Perlin DS**, **Meis JF**. 2018. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother.

11. **Chowdhary A**, **Sharma C**, **Meis JF**. 2017. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog **13**:1–10.

A



B



235 **FIGURE LEGEND**

236 A) Phylogenetic assessment based on core genome SNPs demonstrated the four
237 known geographic clades(1) and placed the California isolate within the South Asia
238 clade. B) Detailed phylogenetic tree describing the South Asia clade including the
239 California isolate and UK outbreak isolate16B15b (3), which both harbored the *FKS1*
240 S639P mutation.